Ivanny M Mtaka is an expert in Immunology at Ifakara Health Institute (Tanzania). Ivanny M Mtaka has authored 9 publications, the most recent in 2026, and is an investigator in 3 clinical trials, 2 of them ongoing. SLR score: 44 (community average: 125). How the SLR is computed.

LeadR Profile

Ivanny M Mtaka Ifakara Health Institute Tanzania
44 ScienceLeadR Reputation 44
Network Map

Immunology

Subspecialties: Infectiology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2024 - 2026

Source: PubMed

Ifakara Health Institute

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 9

Citations

Citations: 353 1st author: 0 Last author: 0 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Safety and immunogenicity of a single-dose adenovirus-vectored rabies vaccine over 1 year in adults and children in Tanzania: interim data from an ongoing, partly randomised, controlled, phase 1b/2 trial.
PMID 42066780 — safety, vaccines, virion, pre-exposure prophylaxis, adenoviridae, vaccination, rabies, viruses, communicable diseases, child, rabies virus, rabies vaccines
Lancet Infect Dis20260
B and T cell responses to pre-erythrocytic R21/Matrix-M and blood-stage RH5.1/Matrix-M malaria vaccines in endemic settings.
PMID 41846927 — cells, malaria, malaria vaccines, blood, serum, vaccines, multiple chronic conditions, malaria, falciparum, biomarkers, vaccination, immune system diseases, memory, t-lymphocytes, b-lymphocytes, memory b cells
Front Immunol20260
Seroprevalence of antibodies to Plasmodium falciparum transmission-blocking target proteins Pfs230D1M and Pfs48/45 in Tanzanian populations of diverse malaria transmission intensity.
PMID 41019048 — malaria, vaccines, antibodies, immune system diseases, child
Front Immunol20250
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial.
PMID 38880111 — cells, malaria, malaria vaccines, safety, blood, serum, vaccines, malaria, falciparum, vaccination, aged, drug-related side effects and adverse reactions, communicable diseases, child
Lancet Infect Dis Top journal202422
First Phase 1b, single-center, age de-escalation trial of the<i>P. falciparum</i>blood-stage malaria vaccine candidate RH5.1/Matrix-M<sup>™</sup>: a delayed boost regimen induces high levels of functional antibodies in 5-17 month old Tanzanian infants
OpenAlex W4393180673 — malaria, malaria vaccines, blood, vaccines, antibodies, malaria, falciparum, vaccination, infant
medRxiv (Cold Spring Harbor Laboratory)20240

Clinical Studies 3

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 1 1
Phase 1/Phase 2 1
Phase 3 1

By status:

Active not recruiting 2
Completed 1

By type:

Interventional 3

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
R21 Matrix M in African Children Against Clinical Malaria
NCT04704830 — malaria, malaria vaccines, vaccines, meningococcal vaccines, multiple chronic conditions, rabies, hepatitis a, hepatitis a vaccines, hepatitis, child, rabies vaccines
Phase 3Active not recruiting2021
A Phase Ib II Study of the Safety and Immunogenicity of the Candidate Rabies Vaccine ChAdOx2 RabG
NCT04270838 — safety, vaccines, rabies, rabies vaccines
Phase 1/Phase 2Active not recruiting2022

LeadR Networks

Main global connection map